RecruitingPhase 1NCT07571174

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA

Sponsor

Eli Lilly and Company

Enrollment

32 participants

Start Date

May 14, 2026

Study Type

INTERVENTIONAL

Conditions

Amyotrophic Lateral Sclerosis

Summary

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LY4256984 for people with amyotrophic lateral sclerosis. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4256984

Administered IT

Locations(9)

UZ Leuven

Leuven, Belgium

McGill University Health Centre

Montreal, Canada

Sunnybrook Research Institute

Toronto, Canada

Universitätsklinikum Schleswig-Holstein

Lübeck, Germany

Universitätsmedizin Rostock

Rostock, Germany

Universitaetsklinikum Ulm

Ulm, Germany

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Spain

Hospital Universitari i Politecnic La Fe

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07571174

Related Trials

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT0732200329 locations

Neurologic Stem Cell Treatment Study

NCT027950523 locations

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT032251441 location

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT0728739711 locations

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT075712009 locations